FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  BOGER JOSHUA S							2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [ VRTX ]										c all applic Directo	,		on(s) to Issi 10% Ov Other (s	vner	
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET						3. Date of Earliest Transaction (Month/Day/Year) 06/22/2004											X Officer (give title Officer (specify below)  Chairman & CEO					
(Street) CAMBRIDGE MA 02139 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)											ndividual or Joint/Group Filing (Check Applicable e)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - No	n-Deriv	vativ	e Se	curit	ies A	cqı	uired, l	Dis	osed o	f, o	r Ben	efici	ally	Owned					
1. Title of Security (Instr. 3)  2. Trans Date (Month/						ear)   i	2A. Deemed Execution Date, if any (Month/Day/Year)			3. Transaction Code (Instr. 8)						4 and Securiti Benefic Owned		s ally following	Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
										Code	v	Amount		(A) or (D)	Price		Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)	
Common Stock 06/22.						4				М		7,000		A	\$6		978,577			D		
Common Stock 06/22						4				<b>S</b> <sup>(1)</sup>		7,000		D	\$10.25		971,577			D		
Common Stock																	10,	106		I	401(k)	
Common Stock																207,500				shares in trust <sup>(2)</sup>		
		-	Гable II -									sed of, onvertil					wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transaction Code (Instr. 8)		ı of			Date Exe piration I onth/Day	Date		7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4)		Securi	S	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly Di or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Da:	te ercisable		expiration Date	Title		Amou or Numb of Share	er						
Stock Option	\$6	06/22/2004			M	7,000 03,			03/	/08/1995 <sup>(</sup>	3) 1	2/07/2004	Common Stock 7,0		7,00	)	\$0	1,520,223		D		

## **Explanation of Responses:**

- 1. Transaction made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1.
- 2. Shares held in trust for Dr. Boger's children. Dr. Boger disclaims beneficial ownership of such shares.
- 3. Right to buy under 1994 Stock and Option Plan, vesting in 20 equal quarterly installments from 12/8/1994.

## Remarks:

Valerie L. Andrews, Attorney-

06/23/2004

**In-Fact** 

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.